生物活性

• 描述Vercirnon is a highly potent antagonist of CCR9, which has been implicated in the aetiology of inflammatory bowel diseases such as Crohn's disease.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT01114607	Crohn's Disease	Phase 1	Completed	-	United States, New York ... more >> GSK Investigational Site Buffalo, New York, United States, 14202 Collapse <<
  NCT01611805	Crohn's Disease	Phase 1	Completed	-	Australia, New South Wales ... more >> GSK Investigational Site Randwick, New South Wales, Australia, 2031 Collapse <<
  NCT00102921	Crohn Disease	Phase 2	Completed	-	United States, California ... more >> Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Colorado Rocky Mountain Clincal Research Golden, Colorado, United States, 80104 Arapahoe Gastroenterology Littleton, Colorado, United States, 80120 United States, Georgia Atlanta Gastroenterology Associates Atlanta, Georgia, United States, 30342 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States United States, New Jersey Comprehensive Clinical Research Berlin, New Jersey, United States, 08009 United States, New York Long Island Clinical Research Associates, LLP Great Neck, New York, United States, 11021 United States, North Carolina Wake Forest Research Raleigh, North Carolina, United States, 27612 United States, Ohio University Hospitals of Cleveland, Div of Gastroenterology Cleveland, Ohio, United States, 44106-5066 United States, Tennessee Digestive Disease Clinic Jackson, Tennessee, United States, 38305 Nashville Medical Research Institute Nashville, Tennessee, United States, 37205 United States, Utah Center for Colon Rectal Disease Salt Lake City, Utah, United States, 84124 United States, Virginia University of Virginia Health System, Digestive Health Center of Excellence Charlottesville, Virginia, United States, 22908 Collapse <<

• 更多
• 参考文献

• [1] Wendt E, Keshav S. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp Gastroenterol. 2015 Apr 7;8:119-30.

  [2] Walters MJ, Wang Y, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010 Oct;335(1):61-9.